key: cord-0851324-j5gmyz9x authors: Demirbaş, Abdullah; Eker, Hediye; Elmas, Ömer Faruk; Ulutaş Demirbaş, Gözde; Atasoy, Mustafa; Türsen, Ümit; Lotti, Torello title: COVID‐19 and human papillomavirus: Paradoxical immunity date: 2021-03-09 journal: J Cosmet Dermatol DOI: 10.1111/jocd.14022 sha: a8b15f6335ea10d910a28cec216118278f03cb77 doc_id: 851324 cord_uid: j5gmyz9x Coronavirus disease 2019 (COVID‐19) is a multisystemic disease that can cause progressive lung failure, organ dysfunction, and coagulation disorder associated with high mortality and morbidity. COVID‐19 is known to either primarily cause skin symptoms or increase existing skin diseases. Human papillomavirus (HPV) is a DNA virus that can cause benign and malignant neoplasms. Mucocutaneous verruca vulgaris are common benign lesions of HPV. Here, we report a case of verruca vulgaris regressed after COVID‐19. The immune system protects us against viruses and diseases, and In the present case, it seems unlikely that the regression of the warts could be related to favipiravir and enoxaparin administered for the treatment of COVID-19. Favipiravir is a new generation viral RNA-dependent RNA polymerase inhibitor and is not expected to show antiviral effects on DNA viruses such as HPV. 7 Enoxaparin is a low molecular weight heparin used in the prophylaxis of thrombovascular complications associated with COVID-19. In a preprint in-vitro study using a pseudotyped model of spike glycoprotein, it has been suggested that enoxaparin may exert an antiviral effect by blocking the entry of SARS-CoV-2. 8 Spike glycoprotein has been demonstrated to bind to heparan sulfate, which is found on the surface of all mammalian cells. 8 Considering that HPV also interacts with the cell surface via interaction of the major capsid protein with heparan sulfate proteoglycans, enoxaparin may show antiviral activity on HPV with a similar mechanism. 9 This potential antiviral activity of enoxaparin, however, is limited to the cell entry stage of the virus, and it seems unlikely that it has an effect on an active viral infection. On the basis of our observation, we conclude that in-depth stud- The patient in this manuscript has given written informed consent to the publication of her case details. Written informed consent was obtained from the patient for publication of this case report. The data that support the findings of this study are available from the corresponding author upon reasonable request. https://orcid.org/0000-0002-3419-9084 Ömer Faruk Elmas https://orcid.org/0000-0002-5474-6508 Ümit Türsen https://orcid.org/0000-0002-5807-6759 Cutaneous manifestations of COVID-19: A review of the published literature Coronavirus-days ın dermatology The trinity of COVID-19: immunity, inflammation and intervention Superficial thrombophlebitis in a patient with COVID 19: heparin treatment after evaluation of D-Dimer Evolving role of immunotherapy in the treatment of refractory warts SARS-CoV-2 infection and impact on female genital tract: an untested hypothesis SARS-CoV-2: from the pathogenesis to potential anti-viral treatments Effective inhibition of SARS-CoV-2 entry by heparin and enoxaparin derivatives Mechanisms of cell entry by human papillomaviruses: an overview